Elsevier

Vaccine

Volume 29, Issue 24, 31 May 2011, Pages 4132-4141
Vaccine

Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection

https://doi.org/10.1016/j.vaccine.2011.03.089Get rights and content

Abstract

Ross River Virus has caused reported outbreaks of epidemic polyarthritis, a chronic debilitating disease associated with significant long-term morbidity in Australia and the Pacific region since the 1920s. To address this public health concern, a formalin- and UV-inactivated whole virus vaccine grown in animal protein-free cell culture was developed and tested in preclinical studies to evaluate immunogenicity and efficacy in animal models. After active immunizations, the vaccine dose-dependently induced antibodies and protected adult mice from viremia and interferon α/β receptor knock-out (IFN-α/βR−/−) mice from death and disease. In passive transfer studies, administration of human vaccinee sera followed by RRV challenge protected adult mice from viremia and young mice from development of arthritic signs similar to human RRV-induced disease. Based on the good correlation between antibody titers in human sera and protection of animals, a correlate of protection was defined. This is of particular importance for the evaluation of the vaccine because of the comparatively low annual incidence of RRV disease, which renders a classical efficacy trial impractical. Antibody-dependent enhancement of infection, did not occur in mice even at low to undetectable concentrations of vaccine-induced antibodies. Also, RRV vaccine-induced antibodies were partially cross-protective against infection with a related alphavirus, Chikungunya virus, and did not enhance infection. Based on these findings, the inactivated RRV vaccine is expected to be efficacious and protect humans from RRV disease.

Introduction

Since 1928, Australia has reported epidemics of a disease characterized by arthritis particularly of the small joints of the hands and feet, often associated with fever and rash [1], [2], [3]. The arthritic symptoms typically last from six weeks to six months, and occasionally for as long as a year, with a correspondingly significant burden on the public health system [4]. Ross River virus (RRV), the causative agent of this syndrome known as epidemic polyarthritis or also RRV disease, is a mosquito-transmitted alphavirus belonging to the Semliki Forest antigenic complex that also Chikungunya (CHIKV), O’nyong-nyong (ONNV) and Barmah Forest viruses (BFV) [5] Although experimental inactivated RRV vaccines have been described previously [6], [7], [8], at present, no licensed vaccine against RRV is available.

In adult, immune-competent mice, RRV challenge does not cause clinical signs, however, a short viremia is induced. Therefore, protection from RRV infection following challenge with the prototype strain T48 was previously evaluated by the absence of viremia [7]. Protection from viremia, however, is not sufficient to define the protective effects of a vaccine in humans, and more specific models are needed for vaccine characterization, particularly when animal models are used to define a correlate of human protection [9].

Recently, an infection model using mice of younger age showing clinical features of arthritic disease has been developed [10], [11]. The model has been extensively characterized with regard to pathogenesis and showed a number of signs similar to those observed in humans such as inflammation and damage of muscle tissue, and prolonged persistence of virus in joint-associated muscle tissue. Since immune-competent mice are susceptible to RRV-induced disease only in the first two weeks of life, the young mouse disease model is useful to study virus-induced pathology and for passive immunization experiments. Moreover, alphaviruses are known as strong inducers of the type-I interferon response [12], and symptomatic and in part lethal infection in interferon-α/β receptor knock-out (IFN-α/βR−/−) mice has been shown for CHIKV and Sindbis virus [13], [14]. Because IFN-α/βR−/− mice show no overt anomalies, but are unable to cope with certain viral infections, despite otherwise normal immune responses [15], [16], they provide a model to investigate the adaptive immune response and perform active protection studies under stringent, frequently lethal conditions.

We have now investigated the immunogenicity and efficacy of an inactivated whole virus RRV vaccine in several mouse models. The vaccine used was an improved version of a previously published vaccine produced in Vero cells [7] now comprising an additional RNA purification step of the primary seed virus and a double virus inactivation by formalin and UV and a further purification step. The evaluation described here was performed in the traditional adult mouse active immunization model [7] and additionally, by active immunization in the IFN-α/βR−/− mouse model. Since immunity induced by inactivated virus vaccines is mainly conferred by neutralizing antibodies, human vaccinee sera were investigated in two different models of passive protection, the adult mouse viremia and the young mouse disease model. In the latter model, we present for the first time animal data on passive protection from human arthritis-like disease signs, and analyze the effect of antibodies on virus persistence and distribution. Further, a correlate of protection was established.

Finally, the phenomenon of antibody-dependent enhancement (ADE) of virus infection in vivo was addressed. ADE has been initially described to be caused by the presence of cross-reactive, yet not cross-neutralizing antibodies to a related virus [17], or by subneutralizing concentrations of antibodies to the same virus [18]. Despite rather limited evidence for its relevance to humans beyond the Dengue viruses [19], [20], ADE by inactivated virus vaccines remains a theoretical concern, recently also raised for RRV [21]. For RRV, it has been possible to enhance infection of cells with RRV by the addition of small amounts of antibody in vitro [22]. This evidence for the potential occurrence of ADE in both of the mouse models was carefully evaluated. The vaccine did neither enhance infection by RRV nor by the related alphavirus Chikungunya virus.

Section snippets

Ethics statement

All animal experiments were reviewed by the Baxter Vienna/Orth Institutional Animal Care and Use Committee (IACUC) and approved by the Austrian regulatory authorities. All animal experiments were conducted in accordance with Austrian laws on animal experimentation and guidelines set out by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Animals were housed in facilities accredited by the AAALAC.

Viruses and cell lines

The mouse virulent RRV prototype strain T48 [23], [24] was

Protection of adult mice from viremia after active immunization

After vaccination of adult mice, twice within 28 days with vaccine doses between 10 μg and down to 0.0025 μg (Table 1), mice developed RRV antibodies as quantified by ELISA, in a clearly dose-dependent fashion. Immunization with 0.039 μg resulted in titers approximately 10-fold over the limit of detection (LOD < 100) and doses of 0.625 μg or higher drove ELISA titers to more than 100-fold the LOD. Similarly, while a vaccine dose of only 0.0025 μg did not afford protection of mice from RRV viremia,

Discussion

Immunogenicity of the RRV vaccine was first studied by active immunization of mice and subsequent challenge to demonstrate protection. The vaccine elicited a similarly strong antibody response both in immune-competent mice (Table 1) and IFN-α/βR−/− mice (Table 2), and fully protected challenged mice from viremia (Fig. 1), or from death and disease, in case of the knock-out mice (Fig. 2). The latter model has been used because alphaviruses are usually efficiently cleared in immune competent mice

Acknowledgments

We thank Elisabeth Hitter for animal work in the active immunization viremia mouse model, and Reinhard Ilk for performing statistical analyses.

References (43)

  • D. Harley et al.

    Ross River virus transmission, infection, and disease: a cross-disciplinary review

    Clin Microbiol Rev

    (2001)
  • A. Suhrbier et al.

    Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses

    Curr Opin Rheumatol

    (2004)
  • J.G. Aaskov et al.

    Surveillance for Ross River virus infection using blood donors

    Am J Trop Med Hyg

    (1998)
  • J.H. Strauss et al.

    The alphaviruses: gene expression, replication, and evolution

    Microbiol Rev

    (1994)
  • Food and Drug Administration. FDA Guidance for Industry: Animal models – Essential elements to address under the Animal...
  • B.A. Lidbury et al.

    Macrophage-induced muscle pathology results in morbidity and mortality for Ross River virus-infected mice

    J Infect Dis

    (2000)
  • T.E. Morrison et al.

    Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis

    J Virol

    (2006)
  • T. Couderc et al.

    A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease

    PLoS Pathog

    (2008)
  • K.D. Ryman et al.

    Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism

    J Virol

    (2000)
  • S. Huang et al.

    Immune response in mice that lack the interferon-gamma receptor

    Science

    (1993)
  • U. Muller et al.

    Functional role of type I and type II interferons in antiviral defense

    Science

    (1994)
  • Cited by (29)

    • Defining a correlate of protection for chikungunya virus vaccines

      2019, Vaccine
      Citation Excerpt :

      For that vaccine candidate, studies in immunocompetent and immunodeficient mice demonstrated that levels of virus-specific total antibodies (measured by ELISA) and neutralizing antibodies (measured by a microneutralization assay), as well as protection against challenge, were vaccine dose-dependent. Passive protection studies in mice further demonstrated that protection was correlated with antibody levels, and that a stronger correlation with neutralizing antibodies over total antibodies could be determined based on serial assessment of protection with sera from vaccinees following multiple vaccine doses [112]. Comparison of vaccine-induced neutralizing antibody titers associated with both active and passive protection in animal models with those in acute phase sera from RRV patients and in sera collected approximately 20 years post-infection, suggested that neutralizing antibody titers ≥10 were conservatively expected to be protective [111,113,114].

    • Ross River virus disease clinical presentation, pathogenesis and current therapeutic strategies

      2017, Microbes and Infection
      Citation Excerpt :

      Only after the third immunisation, however, did the majority of participants achieve seroprotective neutralising antibody titres. Other RRV vaccine candidates and antibody-based therapies, at various stages of preclinical development, take advantage of the cross-protective effect of neutralising antibodies generated against related alphaviruses, such as CHIKV [26,66]. Mutational studies have identified RRV structural proteins that play a major role in RRV pathogenesis, offering opportunities for vaccine development [6].

    • Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model

      2013, Vaccine
      Citation Excerpt :

      Recent epidemiological data highlighted the role of antibodies in protection [12–15]. Moreover, antibody-based therapies clearly established the role of humoral immunity in controlling CHIKV replication [12,16], and in mice passively transferred antibodies protect against arthritogenic alphaviruses [17–20]. The role of T cells in CHIKV infection is still largely unknown.

    • Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: A randomized trial

      2011, Vaccine
      Citation Excerpt :

      The inactivated whole-virus Ross River virus vaccine (Baxter) was produced from a viral seed derived from a Ross River virus isolate from a serologically confirmed case of RRV disease in Queensland, Australia [12]. Viral RNA from this isolate was transfected into Vero cells growing in a serum protein-free cell culture system for vaccine manufacturing as previously described [6,7]. Virus harvested from the serum protein-free Vero cell culture system was inactivated by sequential formalin and ultraviolet light treatment.

    View all citing articles on Scopus
    1

    These authors have equal contribution.

    View full text